Cromolyn Sodium for Treatment of COVID-19 Pneumonia
Key facts
- Who runs it
- Texas Tech University Health Sciences Center, El Paso
- Where
- El Paso, United StatesSee the site
- Trial code
- Status
- Terminated
- Phase
- Phase 3
- People taking part
- 22 people enrolled
- Started
- 15 Nov 2021
- Ended
- 23 May 2024
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Cromolyn Sodium
- Placebo
- Record updated
- 18 November 2024
- Why it stopped
- slow enrollment
Who can take part
- Age
- 18 years to 80 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- COVID-19 symptoms (fever, cough, sore throat, malaise, headache, muscle pain, dyspnea at rest or with exertion, confusion, or respiratory distress),
- diagnosis of COVID-19 pneumonia with an admission chest x-ray demonstrating multilobar ground glass infiltrates consistent with COVID-19 pneumonia
- room air estimated PaO2/FiO2 ratio between 150 -280
- must correct to a pulse oximetry of 90% or better using no more than 5 liters of low flow supplemental oxygen
- must be enrolled within 24 hours of hospital admission
Who cannot take part
- currently on oxygen supplementation greater than low flow nasal cannula (including home oxygen therapy; CPAP for obstructive sleep apnea is not an exclusion)
- immunocompromised due to current use of immunosuppressive drugs or chemotherapy, have a history of HIV/organ transplant/ active hepatitis B or C, or are on hemodialysis or peritoneal dialysis
- experiencing shock (on vasopressors) or multiple organ dysfunction or failure
- are co-infected with influenza A or B
- history of DVT or PE within last 12 weeks
- allergic to cromolyn sodium
- have DNR status or not expected to survive >7 days
- currently pregnant or nursing
- participating in another therapeutic trial
Where in United States
- University Medical Center of El PasoEl Paso, United States
About the trial
What the trial wants to find out
The study hypothesis is that cromolyn, when combined with standard COVID-19 treatment, will improve patient symptoms and reduce the number of days to improved quality of life.
Read full original descriptionShow less
Investigators will study the effects of adding cromolyn to the standard treatment of hospitalized patients with COVID-19 pneumonia and who require supplemental oxygen. Cromolyn will be administered as a nebulized treatment four times a day for four days followed by intranasal administration for two weeks. Investigators may also screen for biomarkers that could indicate inflammatory responses and treatment-induced improvement.
Participants will receive either study drug or placebo which will be administered by nebulization for 4 days followed by 14 days of intranasal administration. Participants will be followed while in the hospital and then as outpatients up to day 21 following randomization.
The 2 groups in the trial
- CromolynTreatment being tested
2mL of 1% cromolyn sodium solution delivered via nebulizer 4 times a day for 4 days followed by 4% cromolyn solution administered intranasally 4 times per day for 14 days
Treatment: Cromolyn Sodium
- PlaceboPlacebo, for comparison
2-3mL of normal saline delivered via nebulizer 4 times a day for 4 days followed by intranasal administration of normal saline 4 times per day for 14 days
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 18 November 2024